Nefopam-d3
Code | Size | Price |
---|
TAR-T19473-100mg | 100mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T19473-500mg | 500mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20°C
Images
Documents
Further Information
Bioactivity:
Nefopam D3 is a deuterium labeled Nefopam. Nefopam is a centrally-acting but non-opioid analgesic drug, and Nefopam targets β-catenin protein level in mesenchymal cells.
CAS:
1346747-15-6
Formula:
C17H19NO
Molecular Weight:
256.36
Purity:
0.98
SMILES:
C(N1CC=2C(C(OCC1)C3=CC=CC=C3)=CC=CC2)([2H])([2H])[2H]
References
Poon R, et al. A high throughput screen identifies Nefopam as targeting cell proliferation in ?-catenin driven neoplastic and reactive fibroproliferative disorders. PLoS One. 2012;7(5):e37940.
Baht GS, et al. Pharmacologically targeting beta-catenin for NF1 associated deficiencies in fracture repair. Bone. 2017 May;98:31-36.
Kim KH, et al. Rediscovery of nefopam for the treatment of neuropathic pain. Korean J Pain. 2014 Apr;27(2):103-11.